Pandemic-Affected Trials Will Need Same Exploratory Analyses That US FDA Used To Save Aducanumab

11 Nov 2020

Use of exploratory methods to understand as much as possible from the two Alzheimer’s disease drug trials that were terminated early for futility is the same type of ‘innovative thinking’ that will be needed to salvage information from neuroscience trials interrupted by the COVID-19, US FDA Office of Neuroscience director Billy Dunn says.

Shipwreck view from above — FDA said it was important to salvage as much information as possible from the terminated Phase III program. • Source: Shutterstock

Pandemic-Affected Trials Will Need Same Exploratory Analyses That US FDA Used To Save Aducanumab

More from US FDA Performance Tracker

More from Regulatory Trackers